Montanide ISA 720 and 51: A new generation of water in oil emulsions as adjuvants for human vaccines

Expert Review of Vaccines

Volumn 1, Issue 1, 2002, Pages 111-118

  Aucouturier, Jerome ^a   Dupuis, L ^a   Deville, S ^a   Ascarateil, S ^a   Ganne, V ^a  

^a SEPPIC   (France)

Author keywords

Adjuvants; Human vaccines; Immunization Montanide ISA

Indexed keywords

ALUMINUM HYDROXIDE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLIPOSOME; IMMUNOLOGICAL ADJUVANT; MINERAL OIL; MONTANIDE ISA; MONTANIDE ISA 51; MONTANIDE ISA 720; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VACCINE; WATER OIL CREAM;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; CANCER; CLINICAL TRIAL; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; DRUG QUALITY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MALARIA; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; VISCOSITY;

ADJUVANTS, IMMUNOLOGIC; DRUG STABILITY; EMULSIONS; HUMANS; MANNITOL; OILS; OLEIC ACIDS; VACCINES; WATER;

EID: 0038176089     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.1.1.111     Document Type: Review

References (41)

1. Cox J, Coulter A. Adjuvants-a classification and review of their modes of action. Vaccine 15(3), 248-256 (1997).
2. Audibert MF, Lise LD. Adjuvants: current status, clinical perspectives and future prospects. Immunol. Today 14(6), 281-284 (1993).
3. Singh M, O'Hagan D. Advances in vaccine adjuvants. Nat. Biotechnol. 17(11), 1075-1081 (1999).
4. Gluck R, Walti E. Biophysical validation of Epaxal Berna, a hepatitis A vaccine adjuvanted with immunopotentiating reconstituted influenza virosomes (IRIV). Dev. Biol. (Basel) 103, 189-197 (2000).
5. Aguado T, Engers H, Pang T, Pink R. 'Novel adjuvants currently in clinical testing november 24, 1998, fondation mérieux, annecy, france: a meeting sponsored by the world health organization'. Vaccine 17, 2321-2328 (1999).
6. Kenney R, Rabinovich R, Pichyangkul S, Price V, Engers H. 2nd Meeting on novel adjuvants currently in/close to human clinical testing. Unpublished.
7. Salk JE, Lewis LJ, Younger JS, Bennett BL. The use of adjuvants to facilitate studies on the immunologic classification of poliomyelitis viruses. Am. J. Hyg. 54, 157-173 (1953).
8. Salk JE, Contakos AB, Laurent AM et al. Use of adjuvants in studies on influenza immunisation. Degree of persistence of antibody in human subjects two years after vaccination. JAMA 151, 1169-1175 (1953).
9. Audibert F, Chedid L. Increase of immune response by administration of metabolizable vegetable oil emulsions C R Acad Sci. Hebd. Seances Acad. Sci D. 280(13), 1629-1632 (1975).
10. Becher P. Emulsion: theory and practice. 2nd edition Reinhold, New York, USA (1965).
11. Lee P, Wang F, Kunishi J et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin Oncol. 19(18), 3836-3847 (2001).
12. Turner JL, Trauger RJ, Daigle AE, Carlo DJ. HIV-1 immunogen induction of HIV-1-specific delayed-type hypersensitivity: results of a double-blind, adjuvant-controlled, dose-ranging trial. AIDS 8, 1429-1435 (1994).
13. Bollinger JN. Metabolic fate of mineral oil adjuvants using 14C-Labeled tracers I: Mineral oil. J. Pharm. Sci. 59, 1084-1088 (1970).
14. Henle W, Henle G. Effect of adjuvants on vaccination or human beings against influenza. Proc. Soc. Exp. Biol. Med. 59, 179-181 (1945).
15. Beebe GW, Simon AK, Vivona S. Follow-up study on Army personnel who received adjuvant influenza virus vaccine 1951-1953. Am. J. Med Sci. 257, 385-405 (1964).
16. Beebe GW, Simon AK, Vivona S. Long-term mortality follow-up of Army recruits who received adjuvant influenza virus vaccine 1951-1953. Am. J. Epidemiol. 95, 337-346 (1972).
17. Page WF, Norman JE, Benenson AS. Long-term follow-up of Army recruits immunised with Freund's Incomplete Adjuvanted vaccine. Vaccine Res. 2(3), 141-149 (1993).
18. Woodhour AF, Metzgar DP, Stim TB, Tytell AA, Hillman MR. New metabolizable immunologic adjuvant for human use: I, development and animal immune response. Proc. Soc. Exp. Biol. Med. 116, 516-523 (1964).
19. Altman A, Dixon FJ. Immunomodifiers in vaccines. Adv. Vet. Sci. Comp. Med. 23, 301-341 (1989).
20. Edelman R. Vaccine adjuvants. Rev. Infect. Dis. 2, 370-383 (1980).
21. Dubovsky P. Review of local reactions with Montanide ISA 720-Oral communication; 'Novel adjuvants currently in/close to human clinical testing'-Fondation Merieux-Annecy-France (2002).
22. Yamshchikov GV, Barnd DL, Eastham S et al. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. Int. J. Cancer 92(5), 703-711 (2001).
23. Jones TR, Obaldia N 3rd, Gramzinski RA et al. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine 17(23-24), 3065-3071 (1999).
24. Aucouturier J, Dupuis L, Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 19(17-19), 2666-2672 (2001).
25. Trauger RJ, Ferre F, Daigle AE et al. Effect of Immunization with Inactivated gp120-Depleted Human Immunodeficiency Virus Type 1 (HIV-1) Immunogen on HIV-1 Immunity, Viral DNA and Percentage of CD4 Cells. J. Infect. Dis. 169, 1256-1264 (1994).
26. Kaeberle ML. Function of carriers and adjuvants in induction of immune responses. Nervig RM, Gough PM, Kaeberle ML, Whetstone CA, editors. Adv. In Carriers and adjuvants for veterinary biologics. Iowa State University Press, USA 11-23 (1986).
27. Waksman BH. Adjuvants and immune regulation by lymphoid cells. Springer Semin. Immunopathol. 2, 5-33 (1979).
28. Krishnan L, Sad S, Patel GB, Sprott GD. Archaeosomes induce long-term CD8+ cytotoxic T-cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T-cell help. J. Immunol. 165(9), 5177-85 (2001).
29. Rao M, Alving CR. Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. Adv. Drug Deliv. Rev. 41(2), 171-188 (2000).
30. Scalzo AA, Elliott SL, Cox J, Gardner J, Moss DJ, Suhrbier A. Induction of Protective Cytotoxic T-cells to Murine Cytomegalovirus by Using a Nonapeptide and a Human-Compatible Adjuvant (MONTANIDE ISA 720). J. Virol. 69(2), 1306-1309 (1995).
31. Visintin A, Mazzoni A, Spitzer JH, Wyllie DH, Dower SK, Segal DM. Regulation of Toll-like receptors in human monocytes and dendritic cells. J. Immunol. 166(1), 249-255 (2001).
32. Le Moinic, Pinoy. Les vaccins en emulsion dans les corps gras ou lipovaccins. Compt. rend. Soc. Biol (1916).
33. Freund J, Casal J, Hismer EP. Sensitization and antibody formation after injection of tubercle bacilli and paraffin oil. Proc. Soc. Exp. Biol. Med. 37, 509 (1937).
34. Dalsgaard K, Hilgers L, Trouve G. Classical and new approaches to adjuvant use in domestic food animals. Adv. Vet. Sci. Comp. Med. 35, 121-128 (1990).
35. Stewart-Tull DES, Shimono T, Kotani S, Knights BA. Immunosuppressive effect in mycobacterial adjuvant emulsions of mineral oils containing low molecular weight hydrocarbons. Int. Arch. Allergy Immunol. 52, 118-128 (1976).
36. Hardegree MC, Kirchstein RL. The toxicity of free fatty acids and Arlacel A. Ann. Allergy 26, 259-268 (1968).
37. Salager JL. Formulation concepts for the emulsion maker. Nielloud F, Mestres GM. Editors, Pharmaceutical emulsions and suspensions and pharmaceutical. Science 105, 19-68 (2000).
38. Lissant KJL. Emulsions and emulsion technology, part III. Kenneth J Lissant editor. Surfact. Sci. Series 6, 206-210 (1984).
39. Ganne V, Eloit M, Laval A, Adam M, Trouve G. Enhancement of the efficacy of a replication-defective adenovirus-vectored vaccine by the addition of oil adjuvants. Vaccine 12(13), 1190-1196 (1994).
40. Kanellos T, Sylvester D, HOward CR, Russell PH.'DNA is as effective as protein at inducing antibody in fish'. Vaccine 17, 965-972 (1999).
41. Ganne ME, Laval A, Aucouturier. J Oil adjuvants enhance the potency of vectored or dna vaccines expressing the pseudorabies virus glycoprotein gp50 gene. Proceedings of the 3rd International symposium on Aujeszky/PRRS - Ploufragan, France (1999).